Ciwon nono da na mahaifa
Idan kai mai ciwon nono ne da ciwon daji na kwai, za ka ga cewa kai ciwon daji ne na maye gurbi na BRCA1/2 bayan ka wuce gwajin kwayoyin halitta, kuma an ceci ranka. A cewar Cibiyar Nazarin Kanjamau ta Duniya, Niraparib, wani magani da aka yi niyya akan kwayar halittar PARP, za a gabatar da shi don tallatawa a cikin kwata na huɗu na wannan shekara saboda ban mamaki lokacin sa na gwaji na asibiti na III. Saboda bayanan gwaji na asibiti mai ban mamaki na wannan magani, yana iya tabbata Yana da tabbacin cewa FDA za ta amince da maganin. Farashin hannun jarin kamfanin samar da magunguna na Tesaro ya tashi daga dala 37 zuwa dala 77 nan take saboda wannan ci gaba.
Wane irin magani ne Niraparib?
It is an oral targeted drug that targets the PARP gene and is not effective for any cancer. It mainly targets cancers with mutations in the BRCA1 / 2 gene, such as ciwon daji na ovarian and breast cancer. It reflects the “precision treatment” concept of modern medicine. Patients with ovarian and ciwon nono need genetic testing to find out if they have a BRCA1 / 2 mutation.
Yaya ban mamaki maganin Niraparib yake?
Tesaro ya fitar da bayanan asibiti na Phase III na Niraparib don masu ciwon daji na ovarian waɗanda suka sake komawa bayan ci gaba na chemotherapy. Sakamakon ya nuna cewa ga ciwon daji na ovarian tare da maye gurbin kwayoyin halitta na BRCA, an dauki Niraparib da baki sau ɗaya kowace rana, kuma matsakaicin rayuwa ba tare da cututtuka ba shine watanni 21, yayin da ƙungiyar kulawa (marasa lafiya da suka karbi chemotherapy kadai) sun sami ci gaba ba tare da ci gaba ba na watanni 5.5. . Watanni 21 da watanni 5.5, lokacin rayuwa kusan sau 4 ya fi tsayi! Wannan adadi yana da ban tsoro sosai, saboda tsawaita rayuwar mafi yawan sabbin magunguna 'yan watanni ne kawai. A wasu kalmomi, marasa lafiya tare da maye gurbin BRCA da ke amfani da Niraparib na iya rayuwa a kan matsakaici fiye da watanni 21. Wannan yana da ban mamaki sosai ga marasa lafiya da ciwon daji na ovarian ci gaba.
Wane irin ciwon daji Niraparib zai iya magancewa?
PARP da BRCA sune manyan kwayoyin halitta guda biyu da ke da alhakin gyara maye gurbin DNA a cikin sel, kuma sune "hanyar kariya ta dama da hagu" don kare lafiyar kwayoyin mu. Sakamakon tasirin muhalli, maye gurbi na DNA yana faruwa a cikin jikinmu kowane lokaci, ko'ina, amma saboda kasancewar waɗannan hanyoyin kariya guda biyu, bayan an tabbatar da maye gurbin DNA, sama da 99.9999% na iya samun nasarar gyarawa, in ba haka ba cutar kansa ta faru. zai yi girma fiye da yanzu.
Amma ga wasu mutane, saboda dalilai na asali ko da aka samu, kwayar halitta ta BRCA ita kanta ta canza kuma ta rasa aikinta, don haka yiwuwar gyara bayan maye gurbin DNA yana da rauni sosai, kuma za a tara ƙarin maye gurbi cikin sauri. Yiwuwar ciwon daji a cikin wannan rukunin yana ƙaruwa sosai.
Although PARP inhibitors are mainly targeted at breast and ovarian cancer, some patients with other cancers also carry BRCA mutations or other DNA repair defects. They theoretically use PARP-targeted drugs to work well, including some prostate cancers. , Fallopian tube cancer, pancreatic cancer, childhood myeloid cutar sankarar bargo, etc. Clinical trials for these cancers are ongoing, and the world is waiting to see the results.
